Tags

Type your tag names separated by a space and hit enter

Oxidative mechanisms and tardive dyskinesia.
CNS Drugs 2003; 17(1):47-62CD

Abstract

Tardive dyskinesia has been and continues to be a significant problem associated with long-term antipsychotic use, but its pathophysiology remains unclear. In the last 10 years, preclinical studies of the administration of antipsychotics to animals, as well as clinical studies of oxidative processes in patients given antipsychotic medications, with and without tardive dyskinesia, have continued to support the possibility that neurotoxic free radical production may be an important consequence of antipsychotic treatment, and that such production may relate to the development of dyskinetic phenomena. In line with this hypothesis, evidence has accumulated for the efficacy of antioxidants, primarily vitamin E (alpha-tocopherol), in the treatment and prevention of tardive dyskinesia. Early studies suggested a modest effect of vitamin E treatment on existing tardive dyskinesia, but later studies did not demonstrate a significant effect. Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted. These approaches may include the use of antioxidants as a preventive measure for tardive dyskinesia or the use of other antioxidants or neuroprotective drugs, such as melatonin, for established tardive dyskinesia.

Authors+Show Affiliations

Department of Psychiatry, University of California San Diego, San Diego, California, USA. jlohr@ucsd.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

12467492

Citation

Lohr, James B., et al. "Oxidative Mechanisms and Tardive Dyskinesia." CNS Drugs, vol. 17, no. 1, 2003, pp. 47-62.
Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17(1):47-62.
Lohr, J. B., Kuczenski, R., & Niculescu, A. B. (2003). Oxidative mechanisms and tardive dyskinesia. CNS Drugs, 17(1), pp. 47-62.
Lohr JB, Kuczenski R, Niculescu AB. Oxidative Mechanisms and Tardive Dyskinesia. CNS Drugs. 2003;17(1):47-62. PubMed PMID: 12467492.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oxidative mechanisms and tardive dyskinesia. AU - Lohr,James B, AU - Kuczenski,Ronald, AU - Niculescu,Alexander B, PY - 2002/12/7/pubmed PY - 2003/4/1/medline PY - 2002/12/7/entrez SP - 47 EP - 62 JF - CNS drugs JO - CNS Drugs VL - 17 IS - 1 N2 - Tardive dyskinesia has been and continues to be a significant problem associated with long-term antipsychotic use, but its pathophysiology remains unclear. In the last 10 years, preclinical studies of the administration of antipsychotics to animals, as well as clinical studies of oxidative processes in patients given antipsychotic medications, with and without tardive dyskinesia, have continued to support the possibility that neurotoxic free radical production may be an important consequence of antipsychotic treatment, and that such production may relate to the development of dyskinetic phenomena. In line with this hypothesis, evidence has accumulated for the efficacy of antioxidants, primarily vitamin E (alpha-tocopherol), in the treatment and prevention of tardive dyskinesia. Early studies suggested a modest effect of vitamin E treatment on existing tardive dyskinesia, but later studies did not demonstrate a significant effect. Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted. These approaches may include the use of antioxidants as a preventive measure for tardive dyskinesia or the use of other antioxidants or neuroprotective drugs, such as melatonin, for established tardive dyskinesia. SN - 1172-7047 UR - https://www.unboundmedicine.com/medline/citation/12467492/Oxidative_mechanisms_and_tardive_dyskinesia_ L2 - https://dx.doi.org/10.2165/00023210-200317010-00004 DB - PRIME DP - Unbound Medicine ER -